Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial
Por:
Balarí, AS, Khan, A, Oriol, A, Mesa, MG, Anwer, F, Encinas, C, Lipe, B, Rodriguez-Otero, P, Chen, P, Lin, HX, Jin, KX, Solomon, T, Taningco, L, Aina, O, Maciag, P and Lonial, S
Publicada:
1 dic 2025
Ahead of Print:
1 dic 2025
Resumen:
Filiaciones:
Balarí, AS:
Univ Barcelona, Inst Catala Oncol Hospitalet, Hematol Dept, IDIBELL, Barcelona, Spain
Khan, A:
Ohio State Univ, Comprehens Canc Ctr, James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA
:
Hosp Germans Trias i Pujol, Catalan Inst Oncol, Badalona, Spain
Hosp Germans Trias i Pujol, Josep Carreras Inst, Badalona, Spain
Mesa, MG:
Vall Hebron Hosp, Hematol Dept, Barcelona, Spain
Anwer, F:
Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland Hts, OH USA
Encinas, C:
Hosp Gen Univ Gregorio Maranon HGUGM, IiSGM, Madrid, Spain
Lipe, B:
UR Med, Dept Med, Rochester, NY USA
Rodriguez-Otero, P:
Clin Univ Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain
Chen, P:
Bristol Myers Squibb, Princeton, NJ USA
Lin, HX:
Bristol Myers Squibb, Princeton, NJ USA
Jin, KX:
Bristol Myers Squibb, Princeton, NJ USA
Solomon, T:
Bristol Myers Squibb, Princeton, NJ USA
Taningco, L:
Bristol Myers Squibb, Princeton, NJ USA
Aina, O:
Bristol Myers Squibb, Princeton, NJ USA
Maciag, P:
Bristol Myers Squibb, Princeton, NJ USA
Lonial, S:
Emory Univ, Winship Canc Inst, Atlanta, GA USA
|